Selecting a continuous glucose monitoring (CGM) partner requires more than checking a sensor’s accuracy or wear time. Quality systems, regulatory compliance, manufacturing resources, software, and after-sales support all affect whether a product can be supplied consistently. A structured evaluation helps buyers identify the evidence that matters before a long-term partnership.
Examine the Quality System Behind the Device
CGM products combine sensing elements, electronics, adhesives, firmware, mobile applications, packaging, and user instructions. Because these components create multiple quality-control points, supplier assessment should begin with the organization’s quality management system rather than the finished product alone.
ISO 13485:2016 is a key international reference for medical-device quality management. ISO states that it covers quality management systems for organizations involved in the design and manufacture of medical devices and related services. It was reviewed and confirmed in 2025, so the 2016 edition remains current.
For a prospective partner, the useful question is how that system operates in practice. Buyers can review procedures for incoming materials, process validation, batch records, traceability, nonconforming products, corrective actions, supplier qualification, and post-market feedback. A certificate is useful evidence, but reviewing underlying controls can provide additional insight into how consistently a supplier manages production.
Verify Accuracy with the Right Context
Accuracy is central to CGM evaluation, but MARD should be interpreted together with study design and intended use. CLSI POCT05 Ed2 addresses point accuracy, trend accuracy, threshold alerts, system stability and reliability, clinical studies, calibration, traceability, cybersecurity, and labeling. The FDA lists CLSI POCTO52nd Edition as a recognized consensus standard for continuous interstitial glucose monitoring.
The specifications published for iCan CGM provide an example of contextual reporting. Published performance data lists a 15-day sensor life, glucose readings every three minutes, real-time connectivity, and an overall MARD of 8.71% for adults. It also identifies a monitoring range of 2.0–25.0 mmol/L and IP28 water resistance.
Supplier due diligence should ask which reference method was used, who participated in the study, where the sensor was worn, how long it was evaluated, and whether performance was assessed across the intended wear period. These details make an accuracy claim more meaningful than a percentage alone.
Check Risk Management and User Safety
A CGM supplier also needs a systematic way to identify and control product risks. ISO 14971:2019 provides an internationally recognized framework covering hazard identification, risk evaluation, risk control, and monitoring across the device life cycle. ISO confirmed the current edition in 2025.
For CGM, risk management can cover sensor insertion, skin contact, signal loss, data transmission, alarms, software behavior, and other foreseeable issues. Biocompatibility deserves attention because wearable components remain in contact with the user. ISO 10993-1:2025 provides principles for evaluating biological safety within a risk-management process.
A partner should explain how risks are assessed, controlled, and monitored after production.
Evaluate Software and Connected Functions
CGM supply chains increasingly include software as part of product experience. Applications can display glucose trends, store historical readings, generate alerts, and produce reports, so supplier evaluation should extend beyond the physical sensor.
IEC 62304 establishes life-cycle requirements for medical-device software and applies to software that is itself a medical device or an integral part of one. Cybersecurity also deserves attention. In February 2026, the FDA issued updated guidance covering cybersecurity design, labeling, and premarket documentation for medical devices with cybersecurity risk.
For suppliers such as Sinocare, buyers can ask how software changes are tested, released, documented, and monitored. They can also examine user permissions, connected data, updates, and communication failures.
Look Beyond Factory Output
Production capacity is not simply the size of a factory. A reliable CGM supply operation depends on qualified component sources, production scheduling, process controls, inspection resources, traceability, inventory planning, and the ability to maintain quality when demand changes.
This matters when a distributor moves from pilot orders to regular commercial volumes. Useful questions include whether critical materials have qualified alternatives, how batches are identified, how deviations are handled, and how production changes are approved.
Sinocare has nine global R&D and manufacturing sites, serves more than 25 million users worldwide, and has a business footprint in 187 countries and regions. These company-reported figures provide context when assessing the organizational infrastructure supporting a CGM business.
Assess Support After the Purchase
The supplier relationship continues after shipment. Documentation, complaint handling, technical support, software maintenance, and regional service can affect customer experience.
For connected CGM systems, support may also involve app updates, data synchronization, replacement procedures, and troubleshooting. For connected CGM systems, post-purchase support may include app updates, data synchronization, replacement procedures, troubleshooting, and user guidance.
When comparing CGM suppliers, it is useful to evaluate these support capabilities together with manufacturing and regulatory documentation. The combination of product development, connected monitoring, and international service capabilities can also be considered when assessing long-term support requirements.
Turning Supplier Due Diligence into a Long-Term Decision
A credible CGM partner should demonstrate more than an attractive product specification. A strong evaluation considers its quality system, accuracy evidence, risk controls, software processes, production infrastructure, traceability, and support capabilities as connected parts of one supply relationship.
The CGM portfolio combines continuous glucose monitoring with connected data management, while the company maintains broader R&D and manufacturing capabilities. For procurement teams, the practical next step is to request documented evidence for each area rather than relying on marketing claims or one performance metric. This makes supplier selection more transparent.
